Literature DB >> 17338144

Evaluation of clinical, macroscopic, and histopathologic response to treatment in nonhypoproteinemic dogs with lymphocytic-plasmacytic enteritis.

M García-Sancho1, F Rodríguez-Franco, A Sainz, C Mancho, A Rodríguez.   

Abstract

BACKGROUND: Lymphocytic-plasmacytic enteritis (LPE) is a common cause of chronic vomiting and diarrhea in dogs. However, little information is available about endoscopic or histopathologic improvement after therapy in dogs with LPE. HYPOTHESIS: The objective was to study the clinical, endoscopic, and histopathologic evolution of LPE during and after immunosuppressive treatment with prednisone and metronidazole. Most dogs also were treated symptomatically with metoclopramide and cimetidine. ANIMALS: Sixteen dogs with LPE and normal serum protein concentrations diagnosed at the Veterinary Medical Teaching Hospital of the Complutense University of Madrid were monitored during and after drug treatment. The control group consisted of 9 dogs that had no gastrointestinal signs for the preceding 12 months.
METHODS: In this prospective clinical treatment trial, clinical, endoscopic, and histopathologic scores were evaluated to describe disease evolution during conventional therapy. Dogs with LPE were monitored for 120 days from the start of treatment. Re-evaluation was performed on post-treatment days 30, 60, 90 (end of treatment), and 120.
RESULTS: The average disease activity index observed in our study fell progressively from its initial value, and the decrease between consecutive re-evaluations was statistically significant until day 60 (P = .04). Our results indicate that 75% of the animals revealed improvement of endoscopic gastric lesions (defined as a reduction of the endoscopic score) after treatment, and 75% exhibited improvement of endoscopic duodenal lesions. Statistical analysis of the data revealed significant differences between pre- and post-treatment gastric and duodenal macroscopic endoscopic lesions (P < .05). On the other hand, treatment did not lead to any significant changes in the severity of the gastric and duodenal histopathologic lesions of the affected dogs. CONCLUSIONS AND CLINICAL IMPORTANCE: Treatment of nonhypoproteinemic dogs with LPE led to clinical and endoscopic improvement, but histopathologic lesions were unchanged during therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17338144     DOI: 10.1892/0891-6640(2007)21[11:eocmah]2.0.co;2

Source DB:  PubMed          Journal:  J Vet Intern Med        ISSN: 0891-6640            Impact factor:   3.333


  22 in total

1.  Chronic Enteropathy in Dogs-Epidemiologic Aspects and Clinical Characteristics of Dogs Presenting at Two Swedish Animal Hospitals.

Authors:  Johanna Holmberg; Lena Pelander; Ingrid Ljungvall; Caroline Harlos; Thomas Spillmann; Jens Häggström
Journal:  Animals (Basel)       Date:  2022-06-09       Impact factor: 3.231

2.  Evaluation of erythrocytes, platelets, and serum iron profile in dogs with chronic enteropathy.

Authors:  Veronica Marchetti; George Lubas; Andrea Lombardo; Michele Corazza; Grazia Guidi; Giovanni Cardini
Journal:  Vet Med Int       Date:  2010-07-28

3.  White spots on the mucosal surface of the duodenum in dogs with lymphocytic plasmacytic enteritis.

Authors:  Mercedes García-Sancho; Angel Sainz; Alejandra Villaescusa; Antonio Rodríguez; Fernando Rodríguez-Franco
Journal:  J Vet Sci       Date:  2011-06       Impact factor: 1.672

Review 4.  Spontaneous and transgenic rodent models of inflammatory bowel disease.

Authors:  Susan Prattis; Abdo Jurjus
Journal:  Lab Anim Res       Date:  2015-06-26

5.  Endoscopic assessment of the duodenum in dogs with inflammatory bowel disease.

Authors:  J E Slovak; C Wang; J A Morrison; K L Deitz; D N LeVine; C Otoni; R R King; L E Gerber; K R Hanson; A P Lundberg; A E Jergens
Journal:  J Vet Intern Med       Date:  2014 Sep-Oct       Impact factor: 3.333

6.  Oral chondroitin sulfate and prebiotics for the treatment of canine Inflammatory Bowel Disease: a randomized, controlled clinical trial.

Authors:  Sergi Segarra; Silvia Martínez-Subiela; Marta Cerdà-Cuéllar; Daniel Martínez-Puig; Alberto Muñoz-Prieto; Fernando Rodríguez-Franco; Antonio Rodríguez-Bertos; Karin Allenspach; Alfonso Velasco; José Cerón
Journal:  BMC Vet Res       Date:  2016-03-10       Impact factor: 2.741

7.  Rifaximin is an effective alternative to metronidazole for the treatment of chronic enteropathy in dogs: a randomised trial.

Authors:  Alessandro Menozzi; Manuel Dall'Aglio; Fausto Quintavalla; Luca Dallavalle; Valentina Meucci; Simone Bertini
Journal:  BMC Vet Res       Date:  2016-10-06       Impact factor: 2.741

8.  Serologic and fecal markers to predict response to induction therapy in dogs with idiopathic inflammatory bowel disease.

Authors:  Cristiane C Otoni; Romy M Heilmann; Mercedes García-Sancho; Angel Sainz; Mark R Ackermann; Jan S Suchodolski; Jörg M Steiner; Albert E Jergens
Journal:  J Vet Intern Med       Date:  2018-04-06       Impact factor: 3.333

9.  Effect of oral administration of metronidazole or prednisolone on fecal microbiota in dogs.

Authors:  Hirotaka Igarashi; Shingo Maeda; Koichi Ohno; Ayako Horigome; Toshitaka Odamaki; Hajime Tsujimoto
Journal:  PLoS One       Date:  2014-09-17       Impact factor: 3.240

10.  Immunophenotype of Peripheral Blood Lymphocytes in Dogs with Inflammatory Bowel Disease.

Authors:  A Galler; B C Rütgen; E Haas; A Saalmüller; R A Hirt; W Gerner; I Schwendenwein; B Richter; J G Thalhammer; N Luckschander-Zeller
Journal:  J Vet Intern Med       Date:  2017-09-01       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.